ライフサイエンスコーパス: revascularisation

1 attacks, strokes, and the need for arterial revascularisation).

2 urrent ischaemia, or the need for myocardial revascularisation).

3 nfarction, or ischaemia-driven target lesion revascularisation).

4 witch controlling both neuronal survival and revascularisation.

5 roke during the past two decades has been on revascularisation.

6 ifedipine, despite an increase in peripheral revascularisation.

7 failure, debilitating stroke, and peripheral revascularisation.

8 rction, or recurrent ischaemia necessitating revascularisation.

9 ociated with off-pump and on-pump myocardial revascularisation.

10 myocardial infarction, and any target-vessel revascularisation.

11 myocardial infarction, and any target-vessel revascularisation.

12 c events, especially the need for myocardial revascularisation.

13 farction, cardiac surgery, and target-vessel revascularisation.

14 ients needed clinically driven target lesion revascularisation.

15 rtery disease, not suitable for conventional revascularisation.

16 ently recover, either spontaneously or after revascularisation.

17 use death, any myocardial infarction, or any revascularisation.

18 or ischaemia-driven hospitalisation without revascularisation.

19 nt, reinfarction, or unplanned target lesion revascularisation.

20 onary angiography, 58.5% underwent inpatient revascularisation.

21 account when selecting patients for carotid revascularisation.

22 l admission for unstable angina, or coronary revascularisation.

23 efinition that did not include target lesion revascularisation.

24 fit from early and frequent monitoring after revascularisation.

25 history of myocardial infarction or coronary revascularisation.

26 , myocardial infarction, stroke, or arterial revascularisation.

27 lesion or vessel revascularisation, and any revascularisation.

28 rasound follow-up is necessary after carotid revascularisation.

29 sis, myocardial infarction, or target-lesion revascularisation]).

30 0 [0.10-0.84], p=0.004) and those undergoing revascularisation (0.37 [0.15-0.93] p=0.02) after 48 h i

31 rction combined with the need for myocardial revascularisation (0.67; 0.46-0.96).

32 .64, 95% CI 0.49-0.84, p=0.001) and coronary revascularisation (0.70, 95% CI 0.52-0.93, p=0.016).

33 4 (8.1%) versus 208 (8.6%) for target-vessel revascularisation (0.93, 0.77-1.14; p=0.495).

34 1.23) and seemingly also by ischaemia-driven revascularisation (1.16, 0.997-1.34) with bivalirudin co

35 ial infarction (46%, p=0.0066), and coronary revascularisation (38%, p=0.037).

36 p=0.0003) and ischaemia-driven target lesion revascularisation (5.3% [169 of 3217] vs 3.9% [90 of 230

37 e of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only

38 rdial infarction (7%, p=0.052), and coronary revascularisation (8%, p=0.034).

39 ower rates of ischaemia-driven target lesion revascularisation (9.4%vs 15.1%, -5.7% [-8.6 to -2.7], 0

40 a history of chronic angina with incomplete revascularisation after percutaneous coronary interventi

41 history of chronic angina who had incomplete revascularisation after percutaneous coronary interventi

42 ve the prognosis of patients with incomplete revascularisation after percutaneous coronary interventi

43 99, overall 0.87 0.79-0.96) and for coronary revascularisation alone (0.84, 0.75-0.94) and unstable a

44 The need for myocardial revascularisation alone was significantly reduced by 42%

45 se alone, and there was less need for urgent revascularisation and fewer major non-fatal ischaemic co

46 Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation d

47 sed in patients undergoing elective coronary revascularisation and reperfusion after acute myocardial

48 y and modified the association between early revascularisation and survival.

49 days, six patients had undergone peripheral revascularisation and were excluded, and ten withdrew or

50 tion for unstable angina requiring unplanned revascularisation) and in sensitivity analyses alternati

51 mortality, all myocardial infarction, or all revascularisation) and the device-oriented composite end

52 nfarction, or ischaemia-driven target lesion revascularisation) and the primary safety outcome measur

53 ion, 65 (9%) had recurrent ischaemia needing revascularisation, and 100 (14%) had one or more of thes

54 ersus 10% (1.50, 1.04-2.17, p=0.032) for any revascularisation, and 5% versus 2% (2.25, 0.93-5.48, p=

55 l infarction, ischaemia-driven target lesion revascularisation, and all revascularisation did not dif

56 ery bypass grafting, target lesion or vessel revascularisation, and any revascularisation.

57 tery disease, intermittent claudication, leg revascularisation, and leg amputation).

58 non-fatal reinfarction, urgent target vessel revascularisation, and major bleeding.

59 ding cardiovascular mortality and morbidity, revascularisation, and non-traumatic amputation within 5

60 uctions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1.

61 ath, myocardial infarction, ischaemia-driven revascularisation, and stent thrombosis.

62 l myocardial infarction, any repeat coronary revascularisation, and stroke.

63 for combined myocardial infarction, coronary revascularisation, and unstable angina (active treatment

64 failure as the first step towards validating revascularisation as a therapeutic option in heart failu

65 farction, or clinically driven target lesion revascularisation at 4 months FINDINGS: 71 stents, 10-15

66 , myocardial infarction, or ischaemia-driven revascularisation at 48 h) by 19% (3.6% vs 4.4%, OR 0.81

67 cardial infarction, and repeat target-lesion revascularisation at 9 months.

68 erence in a long-term composite of death and revascularisation between the 2 methods.

69 ction, or clinically indicated target lesion revascularisation-between the groups at 12 months after

70 imus-Eluting Stent for Percutaneous Coronary Revascularisation (BIOSCIENCE) trial to compare the perf

71 lead not only to recurrent angina and repeat revascularisation but also to acute coronary syndromes.

72 arction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation.

73 ts were reduced by 36% (-55 to -9), coronary revascularisations by 31% (-59 to 16), and rate of strok

74 tients without heart failure (19%) underwent revascularisation compared with 47 with heart failure (3

75 heart failure, the adjusted HR for death in revascularisation compared with receiving medical therap

76 n death, myocardial infarction, and coronary revascularisation; device and procedural success; and an

77 ven target lesion revascularisation, and all revascularisation did not differ between BVS and CoCr-EE

78 cardial infarction, non-fatal stroke, urgent revascularisation due to unstable angina, and hospital a

79 oke, or severe recurrent ischaemia requiring revascularisation during 6 months.

80 Study (COSS), a randomised trial of surgical revascularisation for complete carotid artery occlusion

81 The potential benefit of revascularisation for heart failure is not established.

82 (death, myocardial infarction, or unplanned revascularisation for ischaemia), major bleeding, and ne

83 ts [MACE; death, reinfarction, target vessel revascularisation for ischaemia, or stroke]).

84 ht be an important adjunct or alternative to revascularisation for patients with hibernating myocardi

85 gy (including early coronary angiography and revascularisation) for non-ST-elevation acute coronary s

86 vely) and clinically indicated target-lesion revascularisation (four cases [1%] vs three cases [2%],

87 Patients who underwent revascularisation had better survival in all countries.

88 f incident myocardial infarction or coronary revascularisation, hospital admission with congestive he

89 associated with improved graft function and revascularisation in diabetic mice.

90 ic afterloader can be used to reduce overall revascularisation in patients undergoing treatment for d

91 revascularisation or hospitalisation without revascularisation in patients with a history of chronic

92 percutaneous coronary intervention (PCI) for revascularisation in patients with diabetes and multives

93 rafting (CABG) is the standard treatment for revascularisation in patients with left main coronary ar

94 coronary intervention is used as the mode of revascularisation in patients with STEMI.

95 ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but

96 tinuing the trial and those who had surgical revascularisation in the month before study entry.

97 Revascularisation is a key step for tissue regeneration

98 Myocardial revascularisation is a mainstay in the treatment of symp

99 Incomplete revascularisation is common after percutaneous coronary

100 Myocardial revascularisation may improve symptom status, exercise c

101 Early revascularisation may offer a similar survival benefit i

102 e thrombosis, medical management or surgical revascularisation might be preferred options.

103 th, myocardial infarction, and target-vessel revascularisation occurred in 356 (14.8%) patients who r

104 of 13% (95% CI 7-19; p<0.0001), in coronary revascularisation of 19% (95% CI 15-24; p<0.0001), and i

105 ents allocated to angiography-guided PCI had revascularisation of all identified stenoses.

106 era of stenting and optimum medical therapy, revascularisation of patients with diabetes and multives

107 Revascularisation of renal artery stenosis in heart fail

108 he carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosi

109 educe the composite rate of ischaemia-driven revascularisation or hospitalisation without revasculari

110 time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation wi

111 rventional strategy (angiography followed by revascularisation) or a conservative strategy (ischaemia

112 site of death, myocardial infarction, urgent revascularisation, or bailout glycoprotein IIb/IIIa inhi

113 oke, admission for unstable angina, arterial revascularisation, or cardiovascular death (prespecified

114 on to hospital for unstable angina, arterial revascularisation, or cardiovascular death) and the prot

115 ospitalisation for unstable angina, arterial revascularisation, or cardiovascular death.

116 ath, myocardial infarction, ischaemia-driven revascularisation, or stent thrombosis at 48 h.

117 cute coronary heart disease events, coronary revascularisation, or stroke.

118 ath, myocardial infarction, stroke, coronary revascularisation, or unstable angina; key secondary end

119 ocardial infarction, or repeat target-lesion revascularisation over 290 days compared with 51 [correc

120 t, or stroke or death within 30 days after a revascularisation procedure of the qualifying lesion dur

121 The cost of the initial revascularisation procedure was higher than when a routi

122 early follow-up MRI scan (within 12 h of the revascularisation procedure) and defined as a more than

123 th, non-haemorrhagic stroke, or any arterial revascularisation procedure).

124 related to determination of infarct size and revascularisation procedure.

125 0.75, 95% CI 0.60-0.94; p=0.01) and arterial revascularisation procedures (284 [6.1%] vs 352 [7.6%];

126 r defibrillator, and who were ineligible for revascularisation procedures were randomly assigned (1:1

127 yocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for e

128 onary artery disease, who account for 25% of revascularisation procedures, is much debated.

129 s can be treated successfully using coronary revascularisation procedures, re-occlusion of the treate

130 estenosis and bypass graft failure following revascularisation procedures.

131 Percutaneous transmyocardial laser revascularisation (PTMR) is a proposed catheter-based th

132 The ischaemia-driven target lesion revascularisation rate was 23.8% after 4 months, and the

133 fter 4 months, and the overall target lesion revascularisation rate was 45% after 1 year.

134 6-2.51), and had higher urgent target vessel revascularisation rates (66 [4%] vs 21 [1%]; 2.39, 1.23-

135 balloon angioplasty, stenting, and surgical revascularisation should be considered in these patients

136 ifferences in ischaemia-driven target vessel revascularisation, stent thrombosis, or composite advers

137 ntion (PCI) has replaced thrombolysis as the revascularisation strategy for many patients presenting

138 care delivery systems prioritising immediate revascularisation through percutaneous coronary interven

139 Transmyocardial laser revascularisation (TMLR) is used to treat patients with

140 Transmyocardial revascularisation (TMR) is an operative treatment for re

141 longer lesions must be treated with surgical revascularisation to achieve acceptable long-term outcom

142 STICH) trial, PPAR-2 trial and Heart Failure Revascularisation Trial have all reported their results

143 or non-fatal myocardial infarction, coronary revascularisation, unstable angina, and new angina durin

144 nalysed the risk of stroke within 30 days of revascularisation using a per-protocol analysis.

145 opment of a randomised trial of renal artery revascularisation versus medical therapy in heart failur

146 een DES and PTCA for target lesion or vessel revascularisation was 0.30 (0.17-0.51).

147 After adjusting for co-variables, inpatient revascularisation was associated with approximately a 30

148 al strategy (routine angiography followed by revascularisation) was better than a conservative strate

149 ry or recurrent, and the need for myocardial revascularisation, was always based on objective electro

150 with critical limb ischaemia unsuitable for revascularisation were enrolled from 171 sites in 30 cou

151 selected for management without [corrected] revascularisation were randomly assigned to clopidogrel

152 lls (MSCs) improves islet graft function and revascularisation, which was associated with the mainten

153 coronary syndromes, managed medically and by revascularisation, who would benefit from tirofiban.

154 ficant reductions in target lesion or vessel revascularisation with BMS compared with PTCA (RR 0.68 [

155 ists in the setting of percutaneous coronary revascularisation with intracoronary stents have shown a

156 o compare clinical outcomes for renal artery revascularisation with medical therapy for renal artery